# 诺诚健华 - 最新研发动态与企业里程碑

> 诺诚健华官方新闻通稿、临床试验数据披露及监管审评动态。

- **[2026-09-30] 影响因子47.8 | 《血液学与肿瘤学杂志》：奥布替尼“新组合拳“为中枢神经淋巴瘤带来显著生存获益**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn020260930)

- **[2026-09-24] 诺诚健华宣布与礼来达成研发和授权许可战略合作**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn020260924-InnoCare-Announces-Collaboration-with-Lilly)

- **[2026-09-24] 公子豹投资圈：该重新定义诺诚健华了**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn120260924)

- **[2026-09-21] 诺诚健华登顶北京民营企业专精特新百强榜单第一！**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn020260921)

- **[2026-09-09] 诺诚健华PSMA/STEAP1 双抗ADC ICP-B381获批临床**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn020260909-IND-Approval-of-Bispecific-AD-ICP-B381)

- **[2026-08-25] 医药投资部落：创新药分水岭已至**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn120260826)

- **[2026-08-25] 一图读懂｜诺诚健华2026年中期业绩亮点**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn020260825-InnoCare-2026-Interim-Results)

- **[2026-08-25] 潮药Bar：第二曲线确立，深潜者杀入自免深海**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn0202608251)

- **[2026-08-24] 诺诚健华发布2026年中期业绩报告：盈利持续兑现，管线迎密集里程碑**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn020260824-InnoCare-2026-Interim-Results)

- **[2026-08-18] 诺诚健华拓展血液瘤战略布局 mesutoclax联合疗法头对头对比维奈克拉联合疗法治疗初治AML获批开展III期临床**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn020260818-Approval-of-Phase-III-Clinical-Trial-of-Mesutoclax-for-AML)

- **[2026-08-17] 邀请函｜诺诚健华2026年中期业绩说明会**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn020260817-InnoCare-2026-Interim-Results-Earnings-Call)

- **[2026-08-14] 广州诺诚健华获评 “2026年广东省先进级智能工厂”**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn020260814)

- **[2026-08-12] 《环球时报》刊发崔霁松署名文章：创新药企要抓住行业价值兑现期**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn020260812)

- **[2026-08-10] 央视《新闻联播》聚焦诺诚健华，生物医药创新加速突破**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn020260810)

- **[2026-08-06] 环球时报：【企业家说】崔霁松：创新药企要抓住行业价值兑现期**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn120260806)

- **[2026-08-04] 诺诚健华宣布奥布替尼联合mesutoclax获CDE突破性疗法认定**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn020260804-Orelabrutinib-in-Combination-with-Mesutoclax-Granted-BTD-for-MZL)

- **[2026-07-28] 丁香园Insight：诺诚健华：左手肿瘤，右手自免**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn120260729)

- **[2026-07-27] 诺诚健华新型TYK2抑制剂Fadeucravacitinib（ICP-488）治疗银屑病注册III期研究达到主要终点**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn020260727-TYK2i-Fadeucravacitinib-Meets-Primary-Endpoint-in-Phase-III-Psoriasis Study)

- **[2026-07-21] 《柳叶刀》刊登坦昔妥单抗联合疗法治疗初治DLBCL的Ⅲ期研究结果**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn020260721-The-Lancet-publishes-Phase-3-trial-results-of-tafasitamab-regimen-for-1L-DLBCL)

- **[2026-07-20] 医曜：BMS的留白，诺诚健华的窗口**
  *原文链接*: [阅读全文](https://www.innocarepharma.com/news/activity/cn120260721)